AR070584A1 - Derivados de benzoxazol carboxamida como inhibidores de poli (adp- ribosa) polimerasa (parp) - Google Patents

Derivados de benzoxazol carboxamida como inhibidores de poli (adp- ribosa) polimerasa (parp)

Info

Publication number
AR070584A1
AR070584A1 ARP090100416A ARP090100416A AR070584A1 AR 070584 A1 AR070584 A1 AR 070584A1 AR P090100416 A ARP090100416 A AR P090100416A AR P090100416 A ARP090100416 A AR P090100416A AR 070584 A1 AR070584 A1 AR 070584A1
Authority
AR
Argentina
Prior art keywords
nrarb
group
alkyl
heterocycloalkylthio
heterocycle
Prior art date
Application number
ARP090100416A
Other languages
English (en)
Original Assignee
Lead Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Therapeutics Inc filed Critical Lead Therapeutics Inc
Publication of AR070584A1 publication Critical patent/AR070584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También descritas en la presente, están composiciones farmacéuticas que incluyen al menos, un compuesto descrito en la presente y el uso de un compuesto o composicion farmacéutica descrita en la presente, para tratar enfermedades, trastornos, y condiciones que son aliviadas por la inhibicion de actividad PARP. Reivindicacion 1: Un compuesto de la formula (1) o formula (2) caracterizado porque: Y se selecciona del grupo que consiste de a) un grupo arilo opcionalmente sustituido con 1, 2, o 3 R5; en donde cada R5 se selecciona independientemente del grupo que consiste de alquenilo, alcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, ciano, haloalcoxi, haloalquilo, halogeno, hidroxilo, hidroxialquilo, nitro, oxo, heteroarilo, heteroarilalcoxi, heteroariloxi, heteroariltio, heteroarilalquiltio, heterociclo, heterocicloalcoxi, heterocicloalquiltio, heterociclooxi, heterociclotio, NRARB, (NRARB)alquilo, (NRARB)carbonilo, (NRARB)carbonilalquilo, y (NRARB)sulfonilo, en donde cuando arilo es fenilo, el fenilo es sustituido con al menos un sustituyente seleccionado independientemente del grupo que consiste de alcoxialquilo, heteroarilo, heteroarilalcoxi, heteroariloxi, heteroariltio, heteroarilalquiltio, heterociclo, heterocicloalcoxi, heterocicloalquiltio, heterociclooxi, heterociclotio, (NRARB)alquilo; b) un grupo heteroarilo opcionalmente sustituido con 1, 2, o 3 R5; en donde cada R5 es como se define previamente; c) un grupo L-T en donde L se selecciona del grupo que consiste de alquenileno, alquileno, alquinileno, cicloalquileno y espiroheterociclo y T se selecciona del grupo que consiste de heteroarilo, heteroarilalcoxi, heteroariloxi, heteroariltio, heteroarilalquiltio, heterociclo, heterocicloalcoxi, heterocicloalquiltio, heterociclooxi, heterociclotio, NRARB; d) un anillo heterociclo monocíclico o bicíclico de 4, 5, 6, 7, 8, 9, 10, 11 o 12 elementos no aromático, que tiene 1 o 2 átomos de nitrogeno y, opcionalmente, un átomo de azufre u oxígeno, en donde el heterociclo es opcionalmente sustituido con 1, 2, o 3 R6; en donde cada R6 se selecciona independientemente del grupo que consiste de alquenilo, alcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, ciano, haloalcoxi, haloalquilo, halogeno, hidroxilo, hidroxialquilo, nitro, oxo, heteroarilo, heteroarilalcoxi, heteroariloxi, heteroariltio, heteroarilalquiltio, heterociclo, heterocicloalcoxi, heterocicloalquiltio, heterociclooxi, heterociclotio, NRARB, (NRARB)alquilo, (NRARB)carbonilo, (NRARB)carbonilalquilo, y (NRARB)sulfonilo y en donde cuando el heterociclo es bicíclico, el(los) sustituyente(s) opcional(es) están unidos a cualquiera o ambos de los anillos cíclicos; R1, R2, y R3 son cada uno seleccionados independientemente a partir del grupo que consiste de hidrogeno, halogeno, alquenilo, alcoxi, alcoxicarbonilo, alquilo, cicloalquilo, alquinilo, ciano, haloalcoxi, haloalquilo, hidroxilo, hidroxialquilo, nitro, NRCRD, y (NRCRD)carbonilo; cada RA, RB, RC, y RD son seleccionados independientemente del grupo que consiste de hidrogeno, alquilo, cicloalquilo, y alquilcarbonilo; R4, se selecciona del grupo que consiste de hidrogeno, alquilo, cicloalquilo, alcoxialquilo, haloalquilo, hidroxialquilo, y (NRARB)alquilo; o isomeros, sales, solvatos, formas químicamente protegidas y profármacos de los mismos.
ARP090100416A 2008-02-06 2009-02-06 Derivados de benzoxazol carboxamida como inhibidores de poli (adp- ribosa) polimerasa (parp) AR070584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2669008P 2008-02-06 2008-02-06

Publications (1)

Publication Number Publication Date
AR070584A1 true AR070584A1 (es) 2010-04-21

Family

ID=40932306

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100416A AR070584A1 (es) 2008-02-06 2009-02-06 Derivados de benzoxazol carboxamida como inhibidores de poli (adp- ribosa) polimerasa (parp)

Country Status (7)

Country Link
US (1) US8088760B2 (es)
EP (1) EP2247600A4 (es)
JP (1) JP2011511078A (es)
CN (1) CN101998959B (es)
AR (1) AR070584A1 (es)
TW (1) TWI434847B (es)
WO (1) WO2009099736A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2805945T1 (sl) * 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
BRPI0917119B1 (pt) 2008-08-06 2021-07-13 Medivation Technologies, Inc. Composto, composição farmacêutica, uso dos mesmos e seu processo de fabricação
WO2010083220A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzoxazole inhibitors of poly(adp-ribose)polymerase
US8519176B1 (en) * 2009-10-05 2013-08-27 Boehringer Ingelheim International Gmbh Process for preparation of substituted P-aminophenol
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
CA2788114C (en) 2010-02-08 2018-11-06 Biomarin Pharmaceutical Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
KR20210028747A (ko) 2010-10-21 2021-03-12 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
EP2794565B1 (en) * 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
CN110711188A (zh) 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
BR112015004858A2 (pt) * 2012-09-05 2017-07-04 Bayer Cropscience Ag uso de 2-amidobenzimidazóis, 2-amidobenzoxazóis e 2-amidobenzotiazóis substituídos ou sais dos mesmos como substâncias ativas contra estresse abiótico em plantas
CN103923088B (zh) * 2013-01-11 2016-09-07 上海汇伦生命科技有限公司 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用
CN103059019B (zh) * 2013-01-28 2015-11-04 合肥医工医药有限公司 咪唑[4,5-c]吡啶-7-甲酰胺衍生物、其制法及医药用途
ME03564B (me) 2013-03-13 2020-07-20 Forma Therapeutics Inc DERIVATI 2-HIDROKSI-1-{4-[(4-FENILFENIL)KARBONIL]PIPERAZIN-1-IL}ETAN-1-ONA l SRODNA JEDINJENJA KAO INHIBITORI SINTAZE MASNIH KISELINA (FASN) ZA LEČENJE KANCERA
CN105008329B (zh) 2013-03-21 2018-01-05 默克专利股份公司 作为fasn抑制剂的哌嗪衍生物
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015042397A1 (en) * 2013-09-20 2015-03-26 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN105130973B (zh) * 2014-05-26 2018-05-01 海南国瑞堂中药制药有限公司 5-吡啶基-2-氨基-苯并[d]噁唑衍生物及其制备方法和用途
US20180368404A1 (en) * 2014-11-06 2018-12-27 Basf Se 3-pyridyl heterobicyclic compound for controlling invertebrate pests
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
JP6871169B2 (ja) 2015-03-02 2021-05-12 シナイ ヘルス システム 相同組換え因子
CN104788398B (zh) * 2015-03-24 2017-09-08 上海交通大学 苯并恶唑类化合物及其制备方法和用途
CN104788442A (zh) * 2015-04-02 2015-07-22 湖南华腾制药有限公司 一种取代苯并恶唑衍生物的制备方法
CN105646452B (zh) * 2015-12-24 2018-05-01 北京康立生医药技术开发有限公司 一种蛋白激酶抑制剂的合成方法
MX2018012016A (es) 2016-04-01 2019-01-24 Basf Se Compuestos biciclicos.
CN106008565B (zh) * 2016-06-14 2018-05-15 华南师范大学 一种对有机小分子具有荧光识别功能的多孔金属有机框架的制备方法
CN106187865A (zh) * 2016-07-08 2016-12-07 武汉工程大学 (r)‑1‑叔丁氧羰基‑3‑苄基‑3‑甲酸哌啶的合成及手性拆分方法
CN108752353B (zh) * 2018-04-28 2020-05-08 程春晓 抗卵巢癌药物Rucaparib关键中间体1408282‐26‐7的制备方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
CN109824677B (zh) * 2019-04-03 2021-09-03 江苏开元药业有限公司 治疗卵巢癌药物瑞卡帕布的制备方法
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690926A (en) * 1986-02-03 1987-09-01 Bristol-Myers Company Boxazomycin A and B, new antibiotics containing benzoxazole nucleus
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
JPH0827133A (ja) * 1994-07-08 1996-01-30 Sumitomo Chem Co Ltd 双環式化合物、その用途およびその製造中間体
JP2002528531A (ja) * 1998-11-03 2002-09-03 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−フェニルベンズイミダゾール、その製造法および使用
USRE39608E1 (en) * 1998-11-27 2007-05-01 Abbott Gmbh & Co. Kg Substituted benzimidazoles and their use as PARP inhibitors
GB9914825D0 (en) 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
NZ560969A (en) * 2005-02-17 2010-08-27 Albany Molecular Res Inc Benzoxazole carboxamides for treating chemotherapy-induced vomiting and irritable bowel syndrome
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
ATE536349T1 (de) 2005-09-29 2011-12-15 Abbott Lab In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CA2647545C (en) * 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
ATE523508T1 (de) * 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate

Also Published As

Publication number Publication date
EP2247600A2 (en) 2010-11-10
JP2011511078A (ja) 2011-04-07
US20090197863A1 (en) 2009-08-06
WO2009099736A2 (en) 2009-08-13
TWI434847B (zh) 2014-04-21
TW200946518A (en) 2009-11-16
CN101998959B (zh) 2013-08-28
WO2009099736A3 (en) 2009-10-08
CN101998959A (zh) 2011-03-30
US8088760B2 (en) 2012-01-03
EP2247600A4 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
AR070584A1 (es) Derivados de benzoxazol carboxamida como inhibidores de poli (adp- ribosa) polimerasa (parp)
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20191540A1 (es) DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR056195A1 (es) Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
CA2603784A1 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR054799A1 (es) Derivados de oxindol
AR069524A1 (es) Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento
AR094646A1 (es) Morfinanos sustituidos y su uso
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR043416A1 (es) Un compuesto que comprende derivados de pirazolopiridina, procedimiento para preparar dicho compuesto y sus usos en la manufactura de medicamentos y composiciones farmaceuticas
AR060807A1 (es) Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR065015A1 (es) Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
AR082888A1 (es) Compuestos de piridina para la inhibicion de nampt
ES2662397T3 (es) Inhibidores de la quinasa reguladora de la señal de apoptosis
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR067845A1 (es) Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure